The emergence of multi-drug resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) causes a major threat to public health due to its limited therapeutic options. There is an urgent need for the development of new effective antimicrobial agents and alternative strategies that are effective against resistant bacteria. This study aimed at the development of a reliable method for the extraction, purification, characterization, and quantification of cannabidiolic acid (CBDA) and its decarboxylated form cannabidiol (CBD).
CBD displayed a substantial inhibitory effect on Gram-positive bacteria with minimal inhibitory concentrations ranging from 1 to 2 µg/mL. Time kill analysis and minimal bactericidal concentration revealed potential bactericidal activity of CBDA and CBD. While cannabinoids showed a significant antimicrobial effect on the Gram-positive S. aureus and Staphylococcus epidermidis, no activity was noticed on Gram-negative Escherichia coli and Pseudomonas aeruginosa. A synergy test performed on MRSA with CBD and a range of antibiotics did not indicate a synergetic effect, but noteworthy no antagonist influence either. CBD and CBDA manifested low haemolytic activity on human red blood cells.
CBD displays a potent minimum inhibitory concentration against clinically relevant Gram-positive bacteria. Though it does not possess synergy with any of the tested conventional antibiotics, CBD may still be an interesting addition to current antimicrobial regiments, particularly due to its low toxicity profile and rapid bacterial killing properties.
Goodbody has no association with the organisation that conducted this research and is not in a position to validate the research methods, results or conclusions of the published article. It is provided for awareness of research available that may be of interest only. Any reader should read a range of articles and research to have a balanced and informed view.